⌘K

t

RNS Metadata

Date	19 Aug 2022
Time	16:00:03
Category	Corporate updates
ID	5197W

/Equities/XLON/BPCR/RNS

Net Asset Value(s) and Monthly Factsheet

RNS Number : 5197W

BioPharma Credit PLC

19 August 2022

BIOPHARMA CREDIT PLC (the 'Company')
 
As at the 31 July 2022 the unaudited net asset value per Ordinary Share, including current period revenue, was 101.67 cents. The Company's factsheet will be located on the Company's website, http://bpcruk.com.
 
Dated: 19 August 2022
 
Legal Entity Identifier 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NAVPPMITMTJBBFT

RNS Metadata

Date	19 Aug 2022
Time	16:00:03
Category	Corporate updates
ID	5197W

RNS Number : 5197W

BioPharma Credit PLC

19 August 2022

BIOPHARMA CREDIT PLC (the 'Company')
 
As at the 31 July 2022 the unaudited net asset value per Ordinary Share, including current period revenue, was 101.67 cents. The Company's factsheet will be located on the Company's website, http://bpcruk.com.
 
Dated: 19 August 2022
 
Legal Entity Identifier 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NAVPPMITMTJBBFT